The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function

Sponsor
University of Aarhus
Study ID
NCT02473809
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
30 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    Once daily
  • Placebo — DRUG
    Once daily

Study Details

The purpose of this study is to test whether liraglutide, a drug approved and widely used in the treatment of type 2 diabetes, has an effect on bone mass and bone cell function. Type 2 diabetes may cause multiple complications, and it is well known that patients with type 2 diabetes have a higher risk of fractures. If Liraglutide can be demonstrated to have a positive effect on bone, this may be one among other factors to consider before the decision about specific treatment of type 2 diabetes is made for the individual patient.

Key Dates

Start date
Aug 31, 2015
Status verified
Sep 2018
Primary completion
Oct 31, 2017
Completion
Oct 31, 2017

Study Design

Enrollment
60 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Liraglutide
    Liraglutide ("Victoza"), subcutaneous 1,8 mg once daily for 180 days
  • Placebo Comparator: Placebo
    Saline, subcutaneous once daily for 180 days

Primary Outcome Measure

Change in collagen I cross-linked C-terminal telopeptide measured in serum [ Time Frame: Days 0, 7, 28, 90, 180 ]

Related Studies